YU27902A - Derivati benzodiazepina - Google Patents
Derivati benzodiazepinaInfo
- Publication number
- YU27902A YU27902A YU27902A YUP27902A YU27902A YU 27902 A YU27902 A YU 27902A YU 27902 A YU27902 A YU 27902A YU P27902 A YUP27902 A YU P27902A YU 27902 A YU27902 A YU 27902A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- present
- benzodiazepine derivatives
- compounds
- psychosis
- thiophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
Ovaj pronalazak se odnosi na jedinjenja opšte formule I u kojoj R3 predstavlja fenil; piridin; tiofenil ili tiazolil, koji su opciono supstituisani. Jedinjenja prema ovom pronalasku mogu se primeniti za lečenje ili prevenciju akutnih i/ili hroničnih neuroloških oboljenja kao što su psihoze, šizofrenija, Alchajmerova bolest, poremećaji svesti i gubitak pamćenja.[The present invention relates to compounds of general formula (I) wherein R3 is phenyl; pyridine; thiophenyl or thiazolyl, which are optionally substituted. The compounds according to the present invention can be used for treating or preventing acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99120519 | 1999-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU27902A true YU27902A (sh) | 2004-11-25 |
Family
ID=8239206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU27902A YU27902A (sh) | 1999-10-15 | 2000-09-29 | Derivati benzodiazepina |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US6509328B1 (sh) |
| EP (1) | EP1224175B1 (sh) |
| JP (1) | JP3886805B2 (sh) |
| KR (1) | KR100481386B1 (sh) |
| CN (1) | CN1199954C (sh) |
| AR (1) | AR026028A1 (sh) |
| AT (1) | ATE261945T1 (sh) |
| AU (1) | AU779874B2 (sh) |
| BR (1) | BR0014761A (sh) |
| CA (1) | CA2386980C (sh) |
| CO (1) | CO5251454A1 (sh) |
| CZ (1) | CZ20021663A3 (sh) |
| DE (1) | DE60009116T2 (sh) |
| DK (1) | DK1224175T3 (sh) |
| ES (1) | ES2215738T3 (sh) |
| GC (1) | GC0000207A (sh) |
| HK (1) | HK1051037A1 (sh) |
| HR (1) | HRP20020260B1 (sh) |
| HU (1) | HUP0203294A3 (sh) |
| IL (2) | IL149104A0 (sh) |
| JO (1) | JO2299B1 (sh) |
| MA (1) | MA26832A1 (sh) |
| MX (1) | MXPA02003740A (sh) |
| MY (1) | MY125506A (sh) |
| NO (1) | NO20021691L (sh) |
| NZ (1) | NZ518037A (sh) |
| PE (1) | PE20010759A1 (sh) |
| PL (1) | PL357433A1 (sh) |
| PT (1) | PT1224175E (sh) |
| RU (1) | RU2257382C2 (sh) |
| SI (1) | SI1224175T1 (sh) |
| TR (1) | TR200201026T2 (sh) |
| TW (1) | TWI254044B (sh) |
| WO (1) | WO2001029012A2 (sh) |
| YU (1) | YU27902A (sh) |
| ZA (1) | ZA200202654B (sh) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU27902A (sh) | 1999-10-15 | 2004-11-25 | F. Hoffmann-La Roche Ag. | Derivati benzodiazepina |
| CA2441771C (en) * | 2001-04-12 | 2008-12-30 | F. Hoffmann-La Roche Ag | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i |
| HUP0400851A3 (en) * | 2001-04-12 | 2010-03-29 | Hoffmann La Roche | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| US7531529B2 (en) * | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
| SI1651234T1 (sl) * | 2003-07-25 | 2008-02-29 | Hoffmann La Roche | Kombinacija antagonista mglur2 in inhibitorja ache za zdravljenje akutnih in/ali kronicnih nevroloskih motenj |
| EA011722B1 (ru) | 2004-06-01 | 2009-04-28 | Ф.Хоффманн-Ля Рош Аг | Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5 |
| JP4633123B2 (ja) | 2004-11-05 | 2011-02-16 | エフ．ホフマン−ラ ロシュ アーゲー | イソニコチン酸誘導体の製造方法 |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| WO2007078819A2 (en) * | 2005-12-16 | 2007-07-12 | Arkema Inc. | Low surface energy block co-polymer preparation methods and applications |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080188714A1 (en) * | 2007-02-07 | 2008-08-07 | Boston Scientific Scimed, Inc. | Electromechanical in-situ cleaning of optical elements |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| JP2010524879A (ja) | 2007-04-19 | 2010-07-22 | エフ．ホフマン−ラ ロシュ アーゲー | ジヒドロ−ベンゾ［ｂ］［１，４］ジアゼピン−２−オンスルホンアミド誘導体 |
| SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
| CA2697399C (en) | 2007-09-14 | 2016-01-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| EA016969B1 (ru) * | 2007-09-14 | 2012-08-30 | Аддекс Фарма С.А. | 1,3-двузамещенные-4-фенил-1н-пиридин-2-оны |
| JP5433582B2 (ja) | 2007-11-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用 |
| US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
| BRPI0920354A2 (pt) | 2008-10-16 | 2017-06-27 | Addex Pharmaceuticals Sa | derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2010130424A1 (en) | 2009-05-12 | 2010-11-18 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| WO2012015024A1 (ja) | 2010-07-29 | 2012-02-02 | 大正製薬株式会社 | エチニル－ピラゾール誘導体 |
| US20130137865A1 (en) | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
| AU2011328194B2 (en) | 2010-11-08 | 2015-04-16 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| CN102276592B (zh) * | 2011-06-17 | 2013-10-16 | 大连理工大学 | 一种奥氮平有关物质及其制备方法、分析方法 |
| EP2751095B1 (en) * | 2011-08-29 | 2021-10-27 | Sanford-Burnham Medical Research Institute | Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| CA2853923A1 (en) * | 2011-11-03 | 2013-05-10 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use |
| WO2014064028A1 (en) | 2012-10-23 | 2014-05-01 | F. Hoffmann-La Roche Ag | Mglu2/3 antagonists for the treatment of autistic disorders |
| CN102936223A (zh) * | 2012-11-02 | 2013-02-20 | 江苏中丹药物研究有限公司 | 5-碘-2-甲基苯并咪唑的合成方法及纯化方法 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| UA128346C2 (uk) | 2014-01-21 | 2024-06-19 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
| ES2748633T3 (es) | 2014-01-21 | 2020-03-17 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
| BR112016021727A2 (pt) | 2014-04-23 | 2017-08-15 | Hoffmann La Roche | Antagonistas de mglu2/3 para o tratamento de incapacidades intelectuais |
| WO2015191630A1 (en) | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| CN108586447B (zh) * | 2018-01-19 | 2021-01-29 | 中国人民解放军第四军医大学 | 一种苯二氮杂卓化合物及其制备方法和应用 |
| CN108624674B (zh) * | 2018-03-30 | 2020-11-24 | 青岛泱深生物医药有限公司 | Krt73作为分子靶标在帕金森诊治中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6032775A (ja) | 1983-07-30 | 1985-02-19 | Daikin Ind Ltd | 含フッ素ベンゾジアゼピン類 |
| GB8601004D0 (en) | 1986-01-16 | 1986-02-19 | Fujisawa Pharmaceutical Co | 1,5-benzodiazepine derivatives |
| GB9018601D0 (en) | 1990-08-24 | 1990-10-10 | Fujisawa Pharmaceutical Co | Tricyclic compounds |
| CA2054455A1 (en) | 1990-11-23 | 1992-05-24 | John James Delany | Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides |
| EP0652871B1 (en) | 1992-07-29 | 2001-10-17 | MERCK SHARP & DOHME LTD. | Benzodiazepine derivatives |
| GB9314981D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Spa | Chemical compounds |
| WO1996005818A1 (en) | 1994-08-19 | 1996-02-29 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
| JPH11509847A (ja) * | 1995-07-31 | 1999-08-31 | ノボ ノルディスク アクティーゼルスカブ | ヘテロ環式化合物、それらの調製及び使用 |
| EP0863875B1 (de) | 1995-09-07 | 2003-06-04 | F. Hoffmann-La Roche Ag | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz |
| IL136250A0 (en) * | 1997-11-21 | 2001-05-20 | Nps Pharma Inc | Metabotropic glutamate receptor antagonist compounds |
| YU27902A (sh) | 1999-10-15 | 2004-11-25 | F. Hoffmann-La Roche Ag. | Derivati benzodiazepina |
| CZ20021653A3 (cs) * | 1999-10-15 | 2002-08-14 | F. Hoffmann-La Roche Ag | Nové deriváty benzodiazepinu |
| HUP0400851A3 (en) * | 2001-04-12 | 2010-03-29 | Hoffmann La Roche | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them |
| CA2441771C (en) * | 2001-04-12 | 2008-12-30 | F. Hoffmann-La Roche Ag | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i |
| US6949542B2 (en) * | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
-
2000
- 2000-09-29 YU YU27902A patent/YU27902A/sh unknown
- 2000-09-29 BR BR0014761-3A patent/BR0014761A/pt not_active Application Discontinuation
- 2000-09-29 WO PCT/EP2000/009554 patent/WO2001029012A2/en active IP Right Grant
- 2000-09-29 PT PT00971302T patent/PT1224175E/pt unknown
- 2000-09-29 DE DE60009116T patent/DE60009116T2/de not_active Expired - Lifetime
- 2000-09-29 MX MXPA02003740A patent/MXPA02003740A/es active IP Right Grant
- 2000-09-29 JP JP2001531812A patent/JP3886805B2/ja not_active Expired - Fee Related
- 2000-09-29 ES ES00971302T patent/ES2215738T3/es not_active Expired - Lifetime
- 2000-09-29 CN CNB008142211A patent/CN1199954C/zh not_active Expired - Fee Related
- 2000-09-29 HU HU0203294A patent/HUP0203294A3/hu unknown
- 2000-09-29 AU AU10204/01A patent/AU779874B2/en not_active Ceased
- 2000-09-29 DK DK00971302T patent/DK1224175T3/da active
- 2000-09-29 AT AT00971302T patent/ATE261945T1/de not_active IP Right Cessation
- 2000-09-29 KR KR10-2002-7004831A patent/KR100481386B1/ko not_active IP Right Cessation
- 2000-09-29 EP EP00971302A patent/EP1224175B1/en not_active Expired - Lifetime
- 2000-09-29 CZ CZ20021663A patent/CZ20021663A3/cs unknown
- 2000-09-29 RU RU2002110107/04A patent/RU2257382C2/ru not_active IP Right Cessation
- 2000-09-29 NZ NZ518037A patent/NZ518037A/en unknown
- 2000-09-29 PL PL00357433A patent/PL357433A1/xx not_active Application Discontinuation
- 2000-09-29 IL IL14910400A patent/IL149104A0/xx active IP Right Grant
- 2000-09-29 TR TR2002/01026T patent/TR200201026T2/xx unknown
- 2000-09-29 CA CA2386980A patent/CA2386980C/en not_active Expired - Fee Related
- 2000-09-29 SI SI200030395T patent/SI1224175T1/xx unknown
- 2000-10-07 TW TW089121013A patent/TWI254044B/zh not_active IP Right Cessation
- 2000-10-11 CO CO00077374A patent/CO5251454A1/es not_active Application Discontinuation
- 2000-10-11 JO JO2000170A patent/JO2299B1/en active
- 2000-10-11 GC GCP2000949 patent/GC0000207A/en active
- 2000-10-12 PE PE2000001096A patent/PE20010759A1/es not_active Application Discontinuation
- 2000-10-13 MY MYPI20004818A patent/MY125506A/en unknown
- 2000-10-13 US US09/687,241 patent/US6509328B1/en not_active Expired - Fee Related
- 2000-10-13 AR ARP000105385A patent/AR026028A1/es unknown
-
2002
- 2002-03-27 HR HR20020260 patent/HRP20020260B1/xx not_active IP Right Cessation
- 2002-04-04 ZA ZA200202654A patent/ZA200202654B/en unknown
- 2002-04-10 NO NO20021691A patent/NO20021691L/no not_active Application Discontinuation
- 2002-04-11 IL IL149104A patent/IL149104A/en not_active IP Right Cessation
- 2002-04-15 MA MA26602A patent/MA26832A1/fr unknown
- 2002-11-20 US US10/300,449 patent/US6960578B2/en not_active Expired - Fee Related
-
2003
- 2003-04-17 HK HK03102801A patent/HK1051037A1/xx not_active IP Right Cessation
-
2005
- 2005-06-07 US US11/146,693 patent/US7018998B2/en not_active Expired - Fee Related
-
2006
- 2006-02-27 US US11/363,351 patent/US7151098B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU27902A (sh) | Derivati benzodiazepina | |
| YU26202A (sh) | Derivati benzodiazepina | |
| FI935529A (fi) | Aminometylensubstituerade icke-aromatiska heterocykliska foereningar | |
| NZ595571A (en) | Pyrazole compounds and uses thereof | |
| MY136270A (en) | Processes and intermediates for preparing anti-cancer compounds | |
| WO2000038618A3 (en) | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
| MY122531A (en) | N-(indolecarbonyl) piperazine derivatives | |
| MXPA02008056A (es) | Derivados de 2-oxo-1 pirrolidina, proceso para prepararlos y sus aplicaciones. | |
| TR199900531A2 (xx) | Pirazolopirimidinler ve pirazolotriazinler. | |
| ATE339968T1 (de) | Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| BR0206495A (pt) | Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato | |
| ATE401072T1 (de) | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem | |
| BG105731A (en) | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives | |
| SI1077218T1 (sl) | Peptido-mimetiäśne spojine, ki vsebujejo sekvenco rgd, uporabne kot inhibitorji integrinov | |
| BG104983A (en) | Aryl fused azapolycyclic compounds | |
| GB0412314D0 (en) | Compounds | |
| NZ222640A (en) | Quinolinol derivatives and pharmaceutical compositions | |
| WO2000033788A3 (en) | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof | |
| WO2001002358A3 (en) | Cyclized amide derivatives for treating or preventing neuronal damage | |
| YU22802A (sh) | Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina | |
| PT1373218E (pt) | Derivados de imidazolilo úteis como ligandos do receptor h3 de histamina | |
| AU2178199A (en) | Azetidinecarboxamide derivatives for the treatment of cns disorders | |
| DE60006032D1 (de) | 3-(3-Hydroxyphenyl)-3-amino-propionamidderivate | |
| WO2004096199A3 (en) | Regulation of guanine nucleotide exchange factor |